Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2012-07-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s10549-012-2161-yPMID 22842983PMCID PMC3891577
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Angiotensin II mediates cell survival through upregulation and activation of the serum and glucocorticoid inducible kinase 1.

  2012cited by this paper
• Everolimus in Combination with Exemestane for Postmenopausal Women with Advanced Breast Cancer Who Are Refractory to Letrozole or Anastrozole: Results of the BOLERO-2 Phase III Trial

  2011cited by this paper
• Abstract S1-6: TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients (pts) with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC) with Prior Exposure to Aromatase Inhibitors (AI).

  2010cited by this paper
• Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer

  2010cited by this paper
• Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.

  2010cited by this paper
• RAC3 is a promigratory co-activator of ERα

  2010cited by this paper
• The rapamycin-regulated gene expression signature determines prognosis for breast cancer

  2009cited by this paper
• S6 Kinase 1 Regulates Estrogen Receptor α in Control of Breast Cancer Cell Proliferation*

  2009cited by this paper
• S6 Kinase 1 Regulates Estrogen Receptor (cid:1) in Control of Breast Cancer Cell Proliferation *

  2009cited by this paper
• SGK1 activity in Na+ absorbing airway epithelial cells monitored by assaying NDRG1-Thr346/356/366 phosphorylation

  2009cited by this paper
• An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1*

  2009cited by this paper
• Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic.

  2008cited by this paper
• mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation.

  2008cited by this paper
• mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).

  2008influential reference
• Hsp90 Regulates the Phosphorylation and Activity of Serum- and Glucocorticoid-regulated Kinase-1*

  2008cited by this paper
• Glucocorticoid (GC)-mediated down-regulation of urokinase plasminogen activator expression via the serum and GC regulated kinase-1/forkhead box O3a pathway.

  2008cited by this paper
• Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.

  2007cited by this paper
• Defining the role of mTOR in cancer.

  2007cited by this paper
• Mammalian target of rapamycin regulates the growth of mammary epithelial cells through the inhibitor of deoxyribonucleic acid binding Id1 and their functional differentiation through Id2.

  2006cited by this paper
• A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling

  2006cited by this paper
• Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.

  2006cited by this paper
• A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.

  2006influential reference
• Sulforhodamine B colorimetric assay for cytotoxicity screening

  2006cited by this paper
• Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.

  2005cited by this paper
• Thapsigargin, a novel molecular probe for studying intracellular calcium release and storage

  2005cited by this paper
• Identification of S6 Kinase 1 as a Novel Mammalian Target of Rapamycin (mTOR)-phosphorylating Kinase*

  2005cited by this paper
• Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex

  2005cited by this paper
• New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists

  2004cited by this paper
• Critical Role of Endogenous Akt/IAPs and MEK1/ERK Pathways in Counteracting Endoplasmic Reticulum Stress-induced Cell Death*

  2004cited by this paper
• Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3.

  2004influential reference
• Determining sensitivity to rapamycin and its analogues in breast cancer patients

  2004cited by this paper
• Determinants of Rapamycin Sensitivity in Breast Cancer Cells

  2004cited by this paper
• The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins

  2004cited by this paper
• Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth.

  2001cited by this paper
• Glucocorticoid Receptor-mediated Protection from Apoptosis Is Associated with Induction of the Serine/Threonine Survival Kinase Gene, sgk-1 *

  2001cited by this paper
• Protein Kinase SGK Mediates Survival Signals by Phosphorylating the Forkhead Transcription Factor FKHRL1 (FOXO3a)

  2001cited by this paper
• Serum and glucocorticoid‐inducible kinase (SGK) is a target of the PI 3‐kinase‐stimulated signaling pathway

  1999influential reference
• Activation of serum- and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2.

  1999influential reference
• Thapsigargin, a novel molecular probe for studying intracellular calcium release and storage

  1989cited by this paper

• Tumor exosomal circPTBP3 drives gastric cancer peritoneal metastasis via mesothelial-mesenchymal transition

  2025cites this paper
• Investigating GILZ and SGK-1 in Oral Lesions: Biomarker Potential in Malignant Transformation

  2025cites this paper
• Expression profiles of glucocorticoid-inducible proteins in human papilloma virus-related oropharyngeal squamous cell carcinoma

  2023cites this paper
• Activation of SGK1/ENaC Signaling Pathway Improves the Level of Decidualization in Unexplained Recurrent Spontaneous Abortion

  2023cites this paper
• Autophagy activation in breast cancer cells in vitro after the treatment with PI3K/AKT/mTOR inhibitors

  2022cites this paper
• The Serum- and Glucocorticoid-Inducible Kinase 1 (SGK1) as a Novel Therapeutic Target in Mantle Cell Lymphoma

  2022cites this paper
• SGK1 in Human Cancer: Emerging Roles and Mechanisms

  2021cites this paper
• Si113-prodrugs selectively activated by plasmin against hepatocellular and ovarian carcinoma.

  2021cites this paper
• Expression Profiles of GILZ and SGK-1 in Potentially Malignant and Malignant Human Oral Lesions

  2021cites this paper
• SGK1 Signaling Promotes Glucose Metabolism and Survival in Extracellular Matrix Detached Cells

  2020cites this paper
• The Enigmatic Role of Serum & Glucocorticoid Inducible Kinase 1 in the Endometrium

  2020cites this paper
• The prospect of serum and glucocorticoid-inducible kinase 1 (SGK1) in cancer therapy: a rising star

  2020cites this paper
• Weighted gene correlation network analysis reveals novel biomarkers associated with mesenchymal stromal cell differentiation in early phase

  2020cites this paper
• Estradiol promotes trophoblast viability and invasion by activating SGK1.

  2019cites this paper
• An In silico Approach to Identify High Affinity Small Molecule Targeting m-TOR Inhibitors for the Clinical Treatment of Breast Cancer

  2019cites this paper
• The Parkinson's disease gene PINK1 activates Akt via PINK1 kinase-dependent regulation of the phospholipid PI(3,4,5)P3

  2019cites this paper
• In Preclinical Model of Ovarian Cancer, the SGK1 Inhibitor SI113 Counteracts the Development of Paclitaxel Resistance and Restores Drug Sensitivity

  2019cites this paper
• Potassium acts through mTOR to regulate its own secretion.

  2019cites this paper
• β2-microglobulin has a different regulatory molecular mechanism between ER+ and ER− breast cancer with HER2−

  2019cites this paper
• GR, Sgk1, and NDRG1 in esophageal squamous cell carcinoma: their correlation with therapeutic outcome of neoadjuvant chemotherapy

  2019cites this paper
• Serum- and Glucocorticoid-inducible Kinase 1 is Essential for Osteoclastogenesis and Promotes Breast Cancer Bone Metastasis

  2019cites this paper
• Oncogenic Signalling through Mechanistic Target of Rapamycin (mTOR): A Driver of Metabolic Transformation and Cancer Progression

  2018cites this paper
• Serum- and glucocorticoid-inducible kinase 1 and the response to cell stress

  2018cites this paper
• Involvement of serum glucocorticoid‐regulated kinase 1 in reproductive success

  2017cites this paper
• SGK1 affects RAN/RANBP1/RANGAP1 via SP1 to play a critical role in pre-miRNA nuclear export: a new route of epigenomic regulation

  2017cites this paper
• SGK1/Nedd4–2 signaling pathway regulates the activity of human organic anion transporters 3

  2017cites this paper
• Cytoplasmic translocation of MTA1 coregulator promotes de-repression of SGK1 transcription in hypoxic cancer cells

  2017cites this paper
• Ras-ling with new therapeutic targets for metastasis

  2017cites this paper
• The SGK1 Kinase Inhibitor SI113 Sensitizes Theranostic Effects of the 64CuCl2 in Human Glioblastoma Multiforme Cells

  2017cites this paper
• Next-Generation Sequencing.

  2017cites this paper
• Recent advances in targeting mTOR signaling pathway using small molecule inhibitors

  2017cites this paper
• SGK-1 as a Regulator of Metabolism and Survival of ECM-Detached Cells

  2017cites this paper
• SGK1, the New Player in the Game of Resistance: Chemo-Radio Molecular Target and Strategy for Inhibition

  2016cites this paper
• SGK1 inhibitor reverses hyperglycemia partly through decreasing glucose absorption.

  2016cites this paper
• Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma

  2016cites this paper
• Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer

  2016cites this paper
• Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-clinical Mechanistic Assessment

  2015cites this paper
• Insulin upregulates the expression of epithelial sodium channel in vitro and in a mouse model of acute lung injury: role of mTORC2/SGK1 pathway.

  2015cites this paper
• Glucocorticoid Receptor Activity Contributes to Resistance to Androgen-Targeted Therapy in Prostate Cancer

  2014cites this paper
• Mapping oxidative changes in breast cancer: understanding the basic to reach the clinics.

  2014cites this paper
• New insights into mTOR structure and regulation

  2014cites this paper
• Serum and glucocorticoid inducible kinase, metabolic syndrome, inflammation, and tumor growth

  2013cites this paper
• Serum- and Glucocorticoid-Regulated Kinase 1 Is Required for Nuclear Export of the Ribonucleoprotein of Influenza A Virus

  2013cites this paper
• Therapeutic potential of serum and glucocorticoid inducible kinase inhibition

  2013cites this paper
• Sex-Specific mTOR Signaling Determines Sexual Dimorphism in Myocardial Adaptation in Normotensive DOCA-Salt Model

  2013cites this paper
• SGK1 is regulated by metabolic-related factors in 3T3-L1 adipocytes and overexpressed in the adipose tissue of subjects with obesity and diabetes.

  2013cites this paper